Mark Purcell
Stock Analyst at Morgan Stanley
(1.08)
# 3,423
Out of 4,818 analysts
5
Total ratings
50%
Success rate
-9.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $111.17 | +2.55% | 1 | Jan 23, 2024 | |
| SNY Sanofi | Initiates: Equal-Weight | $55 | $53.54 | +2.73% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $37.50 | +17.35% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $69.55 | +22.21% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $62.63 | +91.60% | 1 | Jan 23, 2024 |
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $111.17
Upside: +2.55%
Sanofi
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $53.54
Upside: +2.73%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $37.50
Upside: +17.35%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $69.55
Upside: +22.21%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $62.63
Upside: +91.60%